Heparanase Mediates Intestinal Inflammation and Injury in a Mouse Model of Sepsis

Journal of Histochemistry and Cytochemistry

Volumn 65, Issue 4, 2017, Pages 241-249

  Chen, Song ^a   He, Ying ^a   Hu, Ziwei ^b   Lu, Siyu ^c   Yin, Xiaohan ^b   Ma, Xiaochun ^b   Lv, Chuanzhu ^a   Jin, Guiyun ^a  

^a HAINAN MEDICAL UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

heparan sulfate; heparanase; intestinal injury; mucosal epithelial glycocalyx; sepsis; syndecan 1

Indexed keywords

GELATINASE B; HEPARANASE; HEPARANASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; N DESULFATED RE N ACETYLATED HEPARIN; SYNDECAN 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UROKINASE; BETA GLUCURONIDASE; CYTOKINE; HEPARAN SULFATE; HEPARIN; HEPARIN, N-DESULFATED;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CECAL LIGATION AND PUNCTURE-INDUCED SEPSIS; CONTROLLED STUDY; ENTERITIS; ENZYME ACTIVITY; GLYCOCALYX; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTESTINE INJURY; MALE; MOUSE; MOUSE MODEL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; IMMUNOLOGY; INTESTINE; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; SEPSIS;

ANIMALS; CYTOKINES; GLUCURONIDASE; HEPARIN; HEPARITIN SULFATE; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTESTINAL MUCOSA; INTESTINES; MALE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; SEPSIS; SYNDECAN-1; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 85018748649     PISSN: 00221554     EISSN: 15515044     Source Type: Journal    
DOI: 10.1369/0022155417692536     Document Type: Article

References (29)

1. Bishop JR, Schuksz M, Esko JD., Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature. 2007;446:1030–7.
2. Kramer KL, Yost HJ., Heparan sulfate core proteins in cell-cell signaling. Annu Rev Genet. 2003;37:461–84.
3. Iozzo RV, Sanderson RD., Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med. 2011;15:1013–31.
4. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U., Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer. 2002;2:521–8.
5. Vreys V, David G., Mammalian heparanase: what is the message? J Cell Mol Med. 2007;11:427–52.
6. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal I, Spector L, Pecker I., Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med. 1999;5:793–802.
7. Goldberg R, Meirovitz A, Hirshoren N, Bulvik R, Binder A, Rubinstein AM, Elkin M., Versatile role of heparanase in inflammation. Matrix Biol. 2013;32:234–40.
8. Lerner I, Hermano E, Zcharia E, Rodkin D, Bulvik R, Doviner V, Rubinstein AM, Ishai-Michaeli R, Atzmon R, Sherman Y, Meirovitz A, Peretz T, Vlodavsky I, Elkin M., Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest. 2011;121:1709–21.
9. Waterman M, Ben-Izhak O, Eliakim R, Groisman G, Vlodavsky I, Ilan N., Heparanase upregulation by colonic epithelium in inflammatory bowel disease. Mod Pathol. 2007;20:8–14.
10. Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, Barthel L, Zemans RL, Bowman JC, Koyanagi DE, Yunt ZX, Smith LP, Cheng SS, Overdier KH, Thompson KR, Geraci MW, Douglas IS, Pearse DB, Tuder RM., The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med. 2012;18:1217–23.
11. Bar-Ner M, Eldor A, Wasserman L, Matzner Y, Cohen IR, Fuks Z, Vlodavsky I., Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood. 1987;70:551–7.
12. Dotan I, Hallak A, Arber N, Santo M, Alexandrowitz A, Knaani Y, Hershkoviz R, Brazowski E, Halpern Z., Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Dig Dis Sci. 2001;46:2239–44.
13. Folwaczny C, Wiebecke B, Loeschke K., Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol. 1999;94:1551–5.
14. Young E., The anti-inflammatory effects of heparin and related compounds. Thromb Res. 2008;122:743–52.
15. Chen S, Zhang X, Sun Y, Hu Z, Lu S, Ma X., Unfractionated heparin attenuates intestinal injury in mouse model of sepsis by inhibiting heparanase. Int J Clin Exp Pathol. 2015;8:4903–12.
16. Hirsh J, Anand SS, Halperin JL, Fuster V, American Heart A. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;103:2994–3018.
17. Ding R, Zhao D, Guo R, Zhang Z, Ma X., Treatment with unfractionated heparin attenuates coagulation and inflammation in endotoxemic mice. Thromb Res. 2011;128:e160–5.
18. Martin L, De Santis R, Koczera P, Simons N, Haase H, Heinbockel L, Brandenburg K, Marx G, Schuerholz T., The synthetic antimicrobial peptide 19-2.5 interacts with heparanase and heparan sulfate in murine and human sepsis. PLoS ONE. 2015;10:e0143583.
19. Lygizos MI, Yang Y, Altmann CJ, Okamura K, Hernando AA, Perez MJ, Smith LP, Koyanagi DE, Gandjeva A, Bhargava R, Tuder RM, Faubel S, Schmidt EP., Heparanase mediates renal dysfunction during early sepsis in mice. Physiol Rep. 2013;1:e00153.
20. Qing Q, Zhang S, Chen Y, Li R, Mao H, Chen Q., High glucose-induced intestinal epithelial barrier damage is aggravated by syndecan-1 destruction and heparanase overexpression. J Cell Mol Med. 2015;19:1366–74.
21. Purushothaman A, Chen L, Yang Y, Sanderson RD., Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem. 2008;283:32628–36.
22. Clark JA, Coopersmith CM., Intestinal crosstalk: a new paradigm for understanding the gut as the “motor” of critical illness. Shock. 2007;28:384–93.
23. Wells JM, Loonen LM, Karczewski JM., The role of innate signaling in the homeostasis of tolerance and immunity in the intestine. Int J Med Microbiol. 2010;300:41–8.
24. Zhang S, Qing Q, Wang Q, Xu J, Zhi F, Park PW, Zhang Y, Chen Y., Syndecan-1 and heparanase: potential markers for activity evaluation and differential diagnosis of Crohn’s disease. Inflamm Bowel Dis. 2013;19:1025–33.
25. Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, Pantesco V, Baudard M, De Vos J, Larroque M, Moehler T, Rossi JF, Reme T, Goldschmidt H, Klein B., Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood. 2007;109:4914–23.
26. Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy JD, Jr Sawyer J, Li JP, Zcharia E, Vlodavsky I, Sanderson RD., Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem. 2007;282:13326–33.
27. Gotte M., Syndecans in inflammation. FASEB J. 2003;17:575–91.
28. Taylor KR, Gallo RL., Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J. 2006;20:9–22.
29. Johnson GB, Brunn GJ, Platt JL., Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor 4. J Immunol. 2004;172:20–4.